Full Press Release Details
Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening
Pediatric Cancer in Children
ANGELES, January 3, 2021 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"),
a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases,
announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for IMX-110 for
the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma. IMX-110, an investigational product, is currently
being evaluated in a Phase 1b/2a clinical trial.
FDA grants Rare Pediatric Disease designation for serious and life-threatening diseases that primarily affect children aged 18 years
or younger and impact fewer than 200,000 people in the United States.
a New Drug Application in the United States for IMX-110 is approved, ImmixBio may be eligible to receive a Priority Review Voucher (PRV)
from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application, or may be sold or transferred.
are pleased by FDA's acknowledgment of the urgent need for a safe and effective treatment for children with this devastating disease,"
stated ImmixBio's Chief Executive Officer Ilya Rachman, M.D., PhD. "We are encouraged by our Phase 1b/2a clinical data in
soft tissue sarcoma. IMX-110 is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment,
severing the critical lifelines between the tumor and its metabolic and structural support. We believe our SMARxT platform generating
Tissue-Specific Therapeutics represents a distinct alternative to the traditional single target, single mutation' development
("RMS") is a high-grade, malignant neoplasm, the most common soft tissue sarcoma in pediatric and adolescent populations
and which rarely occurs in adults. The prevalence of
RMS in the United States is approximately 20,000 children of all ages. The five-year survival rate ranges from 20% to 30% for children
in the high-risk group where cancer spreads widely in the body.
is the first clinical-stage product of ImmixBio's SMARxT Tissue-Specific Platform, which produces Tissue-Specific
Therapeutics that accumulate at intended therapeutic sites at 3 to 5 times the rate of conventional
medicines. The FDA has already granted orphan drug designation (ODD) to IMX-110 for the treatment of soft tissue sarcoma.
recently shared clinical data across multiple soft tissue sarcoma subtypes in several heavily pretreated patients demonstrating median
progression-free survival (PFS) of 4 months with zero drug-related severe adverse events and zero dose interruptions due to toxicity.
The data can be viewed in the Immix Biopharma Corporate Presentation at http://www.immixbio.com/pres
is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting
oncology and immuno-dysregulated diseases. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-SpecificTM Platform
produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Our TME Normalization
Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all
components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and immuno-dysregulated
diseases. In addition to oncology, our pipeline includes Tissue-Specific BiologicTM candidates to treat inflammatory bowel
disease, including ulcerative colitis and Crohn's disease. Learn more at www.immixbio.com.
press release contains "forward-looking statements" Forward-looking statements reflect our current view about future events.
When used in this press release, the words "anticipate," "believe," "estimate," "expect,"
"future," "intend," "plan," or the negative of these terms and similar expressions, as they relate
to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in
this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking
statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They
are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying
on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect
our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other
providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability
to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual
results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of
them. We cannot guarantee future results, levels of activity, performance or achievements. The Company assumes no obligation to update
any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release